These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1278 related items for PubMed ID: 21712347

  • 1. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A.
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [Abstract] [Full Text] [Related]

  • 2. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A.
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [Abstract] [Full Text] [Related]

  • 3. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
    Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, Aebischer P, Schneider BL.
    Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
    [Abstract] [Full Text] [Related]

  • 4. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS, Tang LL, Zheng SS, Zhan RY, Zhou YQ, Goudreau J, Kaufman D, Chen AF.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):155-61. PubMed ID: 15790539
    [Abstract] [Full Text] [Related]

  • 5. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
    Sajadi A, Bauer M, Thöny B, Aebischer P.
    J Neurochem; 2005 Jun 24; 93(6):1482-6. PubMed ID: 15935064
    [Abstract] [Full Text] [Related]

  • 6. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
    Lo Bianco C, Déglon N, Pralong W, Aebischer P.
    Neurobiol Dis; 2004 Nov 24; 17(2):283-9. PubMed ID: 15474365
    [Abstract] [Full Text] [Related]

  • 7. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
    Ericson C, Georgievska B, Lundberg C.
    Eur J Neurosci; 2005 Dec 24; 22(11):2755-64. PubMed ID: 16324109
    [Abstract] [Full Text] [Related]

  • 8. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
    Winkler C, Georgievska B, Carlsson T, Lacar B, Kirik D.
    Neuroscience; 2006 Aug 11; 141(1):521-31. PubMed ID: 16697115
    [Abstract] [Full Text] [Related]

  • 9. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL, Lin Q, Schallert T, Crippens D, Davidson BL, Chang YN, Chiang YL, Qian J, Bardwaj L, Bohn MC.
    Exp Neurol; 1998 Dec 11; 154(2):261-75. PubMed ID: 9878166
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC.
    Gene Ther; 1999 Dec 11; 6(12):1936-51. PubMed ID: 10637445
    [Abstract] [Full Text] [Related]

  • 11. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD, Brown L, Kruegel BR, Wilson A, Tansey MG, Gage FH, Johnson EM, Bartus RT.
    Neurobiol Dis; 2013 Oct 11; 58():38-48. PubMed ID: 23631873
    [Abstract] [Full Text] [Related]

  • 12. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
    Cunningham LA, Su C.
    Exp Neurol; 2002 Apr 11; 174(2):230-42. PubMed ID: 11922664
    [Abstract] [Full Text] [Related]

  • 13. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S, Ranju V, Kalaivani P, Priya RJ, Sumathy H, Sunil AG, Babu CS.
    Neuropharmacology; 2013 Oct 11; 73():98-110. PubMed ID: 23747572
    [Abstract] [Full Text] [Related]

  • 14. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
    Mandel RJ, Snyder RO, Leff SE.
    Exp Neurol; 1999 Nov 11; 160(1):205-14. PubMed ID: 10630205
    [Abstract] [Full Text] [Related]

  • 15. Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease.
    Zhu G, Wang X, Chen Y, Yang S, Cheng H, Wang N, Li Q.
    Planta Med; 2010 Nov 11; 76(16):1820-6. PubMed ID: 20509103
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H.
    J Neurochem; 2004 Oct 11; 91(2):451-61. PubMed ID: 15447678
    [Abstract] [Full Text] [Related]

  • 17. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease.
    Garbayo E, Ansorena E, Lanciego JL, Blanco-Prieto MJ, Aymerich MS.
    Mov Disord; 2011 Aug 15; 26(10):1943-7. PubMed ID: 21661048
    [Abstract] [Full Text] [Related]

  • 18. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
    Bensadoun JC, Déglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P.
    Exp Neurol; 2000 Jul 15; 164(1):15-24. PubMed ID: 10877911
    [Abstract] [Full Text] [Related]

  • 19. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B, Kozlowski DA, Unnerstall JR, Elsworth JD, Tillerson JL, Schallert T, Bohn MC.
    Exp Neurol; 2001 May 15; 169(1):83-95. PubMed ID: 11312561
    [Abstract] [Full Text] [Related]

  • 20. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
    Brizard M, Carcenac C, Bemelmans AP, Feuerstein C, Mallet J, Savasta M.
    Neurobiol Dis; 2006 Jan 15; 21(1):90-101. PubMed ID: 16084732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.